Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications.
The basal cell carcinoma pipeline drugs market research report provides an analysis of the basal cell carcinoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases covering the product development milestones. Additionally, the report provides an overview of key players involved in therapeutic development for basal cell carcinoma and features dormant and discontinued projects.
Basal Cell Carcinoma Pipeline Drugs Market Segmentation by Targets
Some of the targets of the basal cell carcinoma pipeline drugs market Smoothened Homolog, Programmed Cell Death Protein 1, Cytotoxic T Lymphocyte Protein 4, Interferon Gamma, Serine/Threonine Protein Kinase mTOR and Cells Expressing Fibronectin among others.
Basal Cell Carcinoma Pipeline Drugs Market, by Key Targets
For more insights on key targets, download a free report sample
Basal Cell Carcinoma Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action of the basal cell carcinoma pipeline drugs market are Smoothened Homolog Antagonist, Programmed Cell Death Protein 1 Antagonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, Interferon Gamma Activator, Serine/Threonine Protein Kinase mTOR Inhibitor, Cytotoxic To Cells Expressing Fibronectin among others.
Basal Cell Carcinoma Pipeline Drugs Market, by Key Mechanisms of Action
For more insights on key mechanisms of action, download a free report sample
Basal Cell Carcinoma Pipeline Drugs Market Segmentation by Routes of Administration
The routes of administration in the basal cell carcinoma pipeline drugs market are topical, intratumor, intravenous, oral, intralesional and subcutaneous among others.
Basal Cell Carcinoma Pipeline Drugs Market, by Routes of Administration
For more insights on routes of administration, download a free report sample
Basal Cell Carcinoma Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the basal cell carcinoma pipeline drugs market are small molecule, monoclonal antibody, gene therapy, fusion protein, oncolytic virus, and enzyme including a few others.
Basal Cell Carcinoma Pipeline Drugs Market, by Molecule Types
For more insights on molecule type, download a free report sample
Competitive Landscape
Some of the leading companies in the basal cell carcinoma pipeline drugs market are Bristol-Myers Squibb Co, Palvella Therapeutics LLC, Transgene SA, Kintor Pharmaceutical Ltd, MediWound Ltd, Philogen SpA, AiViva BioPharma Inc, Amgen Inc, Bayer AG among others.
Basal Cell Carcinoma Pipeline Drugs Market, by Leading Companies
Basal Cell Carcinoma Pipeline Drugs Market Report Overview
Key Targets | Smoothened Homolog, Programmed Cell Death Protein 1, Cytotoxic T Lymphocyte Protein 4, Interferon Gamma, Serine/Threonine Protein Kinase mTOR and Cells Expressing Fibronectin |
Key Mechanisms of Action | Smoothened Homolog Antagonist, Programmed Cell Death Protein 1 Antagonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, Interferon Gamma Activator, Serine/Threonine Protein Kinase mTOR Inhibitor Cytotoxic To Cells Expressing Fibronectin |
Key Routes of Administration | Topical, Intratumor, Intravenous, Oral, Intralesional and Subcutaneous |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Gene Therapy, Fusion Protein, Oncolytic Virus, and Enzyme |
Key Companies | Bristol-Myers Squibb Co, Palvella Therapeutics LLC, Transgene SA, Kintor Pharmaceutical Ltd, MediWound Ltd, Philogen SpA, AiViva BioPharma Inc, Amgen Inc, Bayer AG |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Amgen Inc
Bayer AG
Biofrontera AG
Biomed
Bristol-Myers Squibb Co
Cannabis Science Inc
Coegin Pharma AS
Evotec SE
Feldan Therapeutics Inc
Genentech USA Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Ingenew Pharmaceuticals Inc
Invion Ltd
IO Biotech Inc
Kintara Therapeutics Inc
Kintor Pharmaceutical Ltd
Laboratories Ojer Pharma SL
Leo Pharma AS
Lytix Biopharma AS
Mayne Pharma Group Ltd
MedC Biopharma Ltd
Medicenna Therapeutics Corp
MediGene AG
Medivir AB
MediWound Ltd
Merck & Co Inc
Morphogenesis Inc
Neonc Technologies Inc
NuCana Plc
Oncorus Inc
Ono Pharmaceutical Co Ltd
Palvella Therapeutics LLC
PellePharm Inc
Philogen SpA
Promontory Therapeutics Inc
QBiotics Group Ltd
Regeneron Pharmaceuticals Inc
Replimune Ltd
Senhwa Biosciences Inc
Singh Biotechnology LLC
Sirnaomics Ltd
Transgene SA
Turn Therapeutics Inc
Varian Biopharmaceuticals Inc
Xencor Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the basal cell carcinoma pipeline drugs market?
Some of the targets of the basal cell carcinoma pipeline drugs market are Smoothened Homolog, Programmed Cell Death Protein 1, Cytotoxic T Lymphocyte Protein 4, Interferon Gamma, Serine/Threonine Protein Kinase mTOR and Cells Expressing Fibronectin among others.
-
What are the mechanisms of action of the basal cell carcinoma pipeline drugs market?
The key mechanism of action of the basal cell carcinoma pipeline drugs market are Smoothened Homolog Antagonist, Programmed Cell Death Protein 1 Antagonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, Interferon Gamma Activator, Serine/Threonine Protein Kinase mTOR Inhibitor Cytotoxic To Cells Expressing Fibronectin among others.
-
What are the routes of administration in the basal cell carcinoma pipeline drugs market?
The routes of administration in the basal cell carcinoma pipeline drugs market are topical, intratumor, intravenous, oral, intralesional and subcutaneous among others.
-
What are the molecule types in the basal cell carcinoma pipeline drugs market?
The molecule types in the basal cell carcinoma pipeline drugs market are small molecule, monoclonal antibody, gene therapy, fusion protein, oncolytic virus, and enzyme including a few others.
-
Which are the leading companies in the basal cell carcinoma pipeline drugs market?
Some of the leading companies in the basal cell carcinoma pipeline drugs market are Bristol-Myers Squibb Co, Palvella Therapeutics LLC, Transgene SA, Kintor Pharmaceutical Ltd, MediWound Ltd, Philogen SpA, AiViva BioPharma Inc, Amgen Inc, Bayer AG among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.